ZW1528 / Zymeworks - LARVOL DELTA

Late Breaking Abstract - ZW1528: A dual-targeting bispecific antibody to broadly suppress airway inflammation by inhibiting IL-4Ra and IL-33 pathways (ERS 2025) - "The results highlight the ability of ZW1528 to inhibit key cytokines involved in pathology of COPD. This concomitant inhibition may translate into broader suppression of airway inflammation, opening avenues for efficient treatment of patients with COPD."

Late-breaking abstract • Chronic Obstructive Pulmonary Disease • Inflammation • Pneumonia • Pulmonary Disease • Respiratory Diseases • IFNG • IL33 • IL4 • IL4R

ZW1528, A Bispecific Antibody Targeting IL-4Rα and IL-33, Potently Inhibits Key Mediators of Airway Inflammation (ATS 2025) - "ZW1528 potently inhibits key mediators of airway inflammation. ZW1528 demonstrated high affinity binding to both IL-4Rα and IL-33 to drive potent blockade of IL-4, IL-13 and IL-33 induced signalling to decrease T2 and T1 immune responses in immune cells. These data highlighting the ability of ZW1528 to block both T1 and T2 inflammation that may translate to better control of COPD in a larger patient population."

Chronic Obstructive Pulmonary Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • FCER2 • IFNG • IL13 • IL33 • IL4

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference (GlobeNewswire) - "Zymeworks...announced the presentation of new preclinical data for ZW1528, a novel IL-4Rα x IL-33 bispecific molecule designed to address respiratory inflammation, at the American Thoracic Society (ATS) International Conference....Suppression of both Type 2 and non-Type 2 responses in primary human immune cells of COPD patients in vitro. Efficacy in vivo in acute and chronic murine models of lung inflammation driven by house dust mites. Extended pharmacokinetics in rodent and non-human primate models, with incorporation of Fc extending half-life optimization."

Preclinical • Chronic Obstructive Pulmonary Disease

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results (GlobeNewswire) - "An abstract highlighting results from recent preclinical research on ZW1528, a novel IL-4R⍺ x IL-33 bispecific molecule, was accepted for poster presentation at the upcoming American Thoracic Society annual meeting: Title: ZW1528, A Bispecific Antibody Targeting IL-4Ra And IL-33, Potently Inhibits Key Mediators Of Airway Inflammation (Abstract: 12571)....Date and Time: May 19, 2025 at 11:30 AM – 13:15 PM PDT."

Preclinical • Immunology • Inflammation • Respiratory Diseases

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026 (GlobeNewswire) - "ADVANCE R&D Program:...Submission of first IND application in AIID expected in 2H-2026 for ZW1528, focused in COPD patients."

IND • Chronic Obstructive Pulmonary Disease

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases (GlobeNewswire) - "ZW1528...is a novel IL-4R⍺ x IL-33 bispecific molecule designed to address respiratory inflammation such as mixed-type chronic obstructive pulmonary disease (COPD)....The Company expects to file an IND and non-U.S. applications to commence Phase 1 clinical studies for ZW1528 in 2H-2026."

New P1 trial • Chronic Obstructive Pulmonary Disease